Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.

Publikation

Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.

Wissenschaftlicher Artikel/Review - 01.09.2022

Patel Kunjal, Huo Yanling, Jao Jennifer, Powis Kathleen M, Williams Paige, Kacanek Deborah, Yee Lynn M, Chadwick Ellen G, Shiau Stephanie, Jacobson Denise L, Brummel Sean S, Sultan-Beyer Leila, Kahlert Christian, Zash Rebecca, Seage George

Zitation

Patel K, Huo Y, Jao J, Powis K, Williams P, Kacanek D, Yee L, Chadwick E, Shiau S, Jacobson D, Brummel S, Sultan-Beyer L, Kahlert C, Zash R, Seage G. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. N Engl J Med 2022; 387:799-809.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

N Engl J Med 2022; 387

Veröffentlichungsdatum

01.09.2022

eISSN (Online)

1533-4406

Seiten

799-809

Kurzbeschreibung/Zielsetzung

Data on the effectiveness and safety of dolutegravir-based antiretroviral therapy (ART) for human immunodeficiency virus type 1 (HIV-1) infection in pregnancy as compared with other ART regimens commonly used in the United States and Europe, particularly when initiated before conception, are limited.